Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Diehl Aircabin Gmbh

Diehl Aviation Laupheim Gmbh

Matthias Hoffmann

Matthias Grauert

Martin Steegmaier

Christoph Hoenke

Georg Dahmann

Steffen Breitfelder

Trixi Brandl

Flavio Solca

John Scott

Jasna Klicic

Udo Maier

Stefan Scheuerer

Dennis Fiegen

Clive Mccarthy

Guenter Linz

Alexander Pautsch

Michael Paul Pieper

Andreas Schnapp

Domnic Martyres

Peter Seither

Anne T Joergensen

Horst Dollinger

Gerhard Schaenzle

Sandra Handschuh

Edward Walker

Stephen East

Gisela Schnapp

Ingo Pragst

Klaus Erb

Jens Juergen Quant

Riccardo Giovannini

Peter Sieger

Christian Eickmeier

Rudolf Hauptmann

Darryl McConnell

Marc Grundl

Anke Baum

Gerald Pohl

Steffen Steurer

Christian Gnamm

Thomas Weiser

Andreas Schoop

Norbert Redemann

Gerd Kraemer

Adrian Carter

Bodo Betzemeier

Ulrike Weyer-Czernilofsky

Maria Impagnatiello

Florian Colbatzky

Georg Rast

Jan Magnus Kriegl

Thomas Gerstberger

Ulrike Kuefner-Muehl

David James Lamb

Spencer Charles R Napier

Thierry Bouyssou

Annette Schuler-Metz

Thorsten Lehmann-Lintz

Erich Lehr

Harald Engelhardt

Wolfram Gaida

Werner Rall

Heinz Stadtmueller

Rolf Schmid

Stefan Matthias Blech

Joachim Mierau

Eckhart Bauer

Frank Hilberg

Dirk Kessler

Christopher John Montague Meade

Daniel Bischoff

Michael Philip Mazanetz

Irene Waizenegger

Bernd Krist

Daniel Robert Fandrick

Stefan Ludwig Michael Wollin

Serge Convers-Reignier

Rolf Herter

Silke Hobbie

Christian Klein

Ralph Brueckner

Takeshi Kono

Andreas Zoephel

Frederic Jacques Marlin

Michael Gmachl

Robert John Scott

Jens Jurgen Quant

Birgit Jung

Hans Briem

Werner Kummer

Georg Speck

Stefan Peters

Martin Thomas Fleck

Wolf-Dietrich Bechtel

Ulrich Reiser

Frank Buettner

Stephan Karl Zahn

Rainer Palluk

Lars Van Der Veen

Ulrich Guertler

The invention relates to new substituted heteroaryls of formula 1 wherein

Heteroaryl SYK inhibitors

The invention relates to new substituted heteroaryls of formula 1 or of formula 1' wherein A is either N or CH,wherein Ris selected from the group consisting of &#x2014;C-alkyl, &#x2014;C-haloalkyl, F, Br, Cl,wherein Y is selected from &#x2014;O&#x2014; or &#x2014;CH&#x2014;,and wherein Ris defined as in claim, and the pharmaceutically acceptable salts thereof,and the use of these aforementioned compounds for the treatment of diseases such as asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.

Pyrazolyl-substituted heteroaryls and their use as medicaments

The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R, M and Rare defined according to claim, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis. 

Heteroaryl Syk inhibitors

The invention relates to new substituted heteroaryls of formula 1 or of formula 

A method for manufacturing a cladding element for a passenger cabin of a vehicle is provided. A first layer is introduced into a forming shell. A support layer is provided onto the first layer, such that the first layer extends beyond an edge of the support layer. An elastic material strip is provided onto a portion of the first layer hat extends beyond the support layer, such that the material strip is flush with the edge of the support layer. A second layer is provided onto the support layer, such that a portion of the second layer extends beyond the edge of the support layer and is superimposed on the material strip. The forming shell is closed and a pressure is exerted on the layer arrangement accommodated in the forming shell at a temperature between 50&#xb0; C. to 100&#xb0; C., to form a sandwich structure.

Method for the manufacturing of a cladding element for a passenger cabin of a vehicle

Disclosed are substituted quinolines of formula 1 whereinRand Rare defined herein, the processing of making and using the same.

Substituted quinolines and their use as medicaments

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein wherein n is either 0 or 1,

Substituted naphthyridines and their use as medicaments

The invention relates to new amino-indole-substituted imidazolyl-pyrimidines of formula 1 whereinR, R, R, Rand Rare defined as in claimand pharmaceutically acceptable salts thereof and the use of these compounds for the preparation of a medicament for treating a disease selected from asthma, COPD, rheumatoid arthritis, specific lymphomas and specific diseases of the nervous system.

Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments

The invention relates to new substituted naphthyridines of formula 1, as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates or solvates thereof, wherein

4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments

Object of the present invention are novel substituted compounds of the formula 1, wherein A, R, R, Rand Rare defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.

Substituted piperidines as CCR3 antagonists

The invention relates to new substituted pyridinyl-pyrimidines of formula 

Substituted pyridinyl-pyrimidines and their use as medicaments

Therapeutic methods employing substituted piperidines which are CCR3 antagonists

The invention relates to novel substituted naphthyridines of formula 1 as well as pharmacologically acceptable salts, diastereomers, enantiomers, racemates, hydrates, or solvates thereof. In formula 1, Rcan represent a group A selected from among the group comprising &#x2014;O&#x2014;R, &#x2014;NRR, &#x2014;CRRR, -(ethyne)-R, &#x2014;S&#x2014;R, &#x2014;SO&#x2014;R, and SO&#x2014;R, or Rrepresents a group B selected from among the group comprising: &#x2014;C-aryl; &#x2014;a five-membered to ten-membered, monocyclic or bicyclic heteroaryl containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heteroaryl is linked to the structure according to formula 1 via a C atom or an N atom; &#x2014;a three-membered to ten-membered, monocyclic or bicyclic, saturated or partially saturated heterocycle containing 1 to 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said heterocycle is linked to the structure according to formula 1 via a C atom or an N atom; and &#x2014;a 5-membered to 11-membered spiro group which can optionally contain 1, 2, or 3 heteroatoms independently selected from among the group comprising N, O, and S, wherein said spiro group is linked to the structure according to formula 1 via a C atom or an N atom, wherein said group B can be optionally substituted as described in claims, and R, R, R, R, and m can have the meanings indicated in claim. The invention also relates to pharmaceutical compositions containing said compounds. 

Growing community of inventors

Mittelbiberach, Germany

Matthias Hoffmann